...
首页> 外文期刊>Clinical and Translational Medicine >A novel signature based on pairwise PD‐1/PD‐L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma
【24h】

A novel signature based on pairwise PD‐1/PD‐L1 signaling pathway genes for predicting the overall survival in patients with hepatocellular carcinoma

机译:一种基于成对PD-1 / PD-L1信号通路基因的新型签名,用于预测肝细胞癌患者的整体存活

获取原文
           

摘要

Hepatocellular carcinoma (HCC) is ranked as the most prevalentsubgroupoflivermalignanciesintheworld,rep- resenting about 90% of primary liver cancers. 1 To date, no widely accepted molecular biomarkers are available for survival stratification with HCC. 2,3 Recently, a novel algorithm was developed based on the relative orderings of mRNA expression patterns and had yielded excellent results. 4,5 Substanti albreak through sha vebeen founded in programmed death 1 (PD-1)/ programmed death 1 ligand (PD-L1) signaling pathway in various cancers. 6 Here, we used the TCGA cohort to develop a signature and other two databases to confirm the prognostic model based on pairwise PD-1/PD-L1 signaling pathway genes.
机译:肝细胞癌(HCC)被排名为最普遍的upgroupofofligermalignanciesintheworld,令人生畏的肝癌约90%。 1迄今为止,没有广泛接受的分子生物标志物可用于与HCC一起存活分层。 2,3最近,基于MRNA表达模式的相对排序开发了一种新颖的算法,并且产生了优异的结果。 通过SHA Vebeen在各种癌症中成立于编程的死亡1(PD-1)/编程死亡1配体(PD-L1)信号通路的4,5个。 6在这里,我们使用TCGA队列来开发签名和其他两个数据库,以确认基于成对PD-1 / PD-L1信号通路基因的预后模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号